阻滞剂

基本解释 (translations)

blocker  ·  paralyzer  ·  retardants  ·  paralysor

词组短语

retarding agent · blocking agent

与阻滞剂相关的网络例句 [注：此内容来源于网络，仅供参考]

The other 20 cases in control group were treated by antibiotic and alpha-lA receptor blockader.

治疗组应用川参通注射液加口服抗生素、α1A-受体阻滞剂；对照组应用川参通注射液加α1A-受体阻滞剂。

According to the echocardiography,enlarged internal diameter of left ventricle was found in 8 patients and short-axis fractional shortening of left ventricle 5% in 3 patients.Six out of the above 8 patients presented with shortening of accerlerating time,decreasing of accerlerating time/right ventricular ejective time value and moving forward of spectral peak in different degrees.All patients were given antianginal drugs such as β-recepter blockers,nitrate preparations and part by angiotensin converting enzyme inhibitor,diuretics and digoxin,The illncss of 29 patients were gradually controlled within one week.Three patients with AD were complicated by acute left heart failure.No obvious changes in FS of left ventricle were found on echocardiography by bed.

测量肺动脉瓣口血流频谱，左心室内径增大的8例中有6例出现不同程度的血流加速时间缩短，血流加速时间/右心室射血时间比值减小，频谱峰值前移。31例均给予β受体阻滞剂、硝酸酯类等抗心绞痛治疗，部分给予血管紧张素转换酶抑制剂、利尿剂和地高辛，其中29例在1周内卧位型心绞痛逐步得到控制。3例卧位型心绞痛发作时合并急性左心衰竭者，在床旁观察超声心动图，发现左心室短轴缩短率无显著变化，给予利尿剂、减轻前后负荷等治疗，急性左心衰竭得以纠正。

Methods］By observing the cytoplasmic Ca2+ concentration change of single cardiocyte in I/R status and the effect of Na+/H+ permutoid retarder to Ca2+ concentration in different phases (diabetes pure oxygen-lack deficit group called DM group,the oxygen deficit/reaeration on entire journey for medicine group called DM-EIPA group, the first group giringmedicine before reaeration on called DM-EIPA 1 group, and the second group giringmedicine before reaeration on called DM-EIPA 2 group) to detect the protection mechanism of Na+/H+ permutoid retarder to diabetic mouse cardiac muscle cell oxygen deficit/reaeration injury.

方法］ 通过观察糖尿病鼠单个心肌细胞在缺氧/复氧时细胞胞浆Ca2+浓度的动态变化以及Na+/H+交换体阻滞剂在不同时相（糖尿病单纯缺氧组即DM组，缺氧/复氧全程给药组即DM-EIPA组，复氧前给药1组即DM-EIPA 1组，复氧前给药2组即DM-EIPA 2组）对Ca2+浓度的影响来研究Na+/H+交换体阻滞剂对糖尿病鼠心肌细胞缺氧/复氧损伤的保护机制。

In acute experiments, APO-induced stereotypy and locomotion could be blocked by both selective 〓 antagonists SCH 23390 and 〓 antagonist sulpiride, and they had a synergistic effect when used in combination.

急性实验中，选择性〓阻滞剂SCH 23390和〓阻滞剂舒必利能有效地对抗APO诱发的定型活动和肢体运动，两药相加有协同作用。

Results］In 108 patients (93.1%) routinely took antiplatelet drug orally;75 patients (64.7%) common took ACEI orally; 82 patients (70.7%) usually took beta-blocker orally; only 39 patients (33.6%) insisted on taking lipid-lowering drug orally;26 symptomless patients long-term took orally nitrate;24 symptomless patients long-term took Calcium antagonists.

结果］ 108例（93.1％）患者常规口服抗血小板药物，存在主要问题是部分患者用量偏低；75例（64.7％）患者服用ACEI；82例（70.7％）患者常规口服β-受体阻滞剂，心率达标率为39％；只有39例（33.6％）患者坚持服用调脂药；26例患者无症状长期口服硝酸酯类药物；24例患者长期口服钙通道阻滞剂。

Fie years after initiation of treatment, 79% patients were still on renin-angiotensin inhibitors, 65% on -blockers, 56% on spironolactone, and 83% on statins. Notably, multiple drug treatment and increased seerity of heart failure was associated with persistence of treatment. Nonpersistence with renin-angiotensin inhibitors,-blockers, and statins was associated with increased mortality with hazard ratios for death of 1.37 (95% CI, 1.31 to 1.42), 1.25 (95% CI, 1.19 to 1.32), 1.88 (95% CI, 1.67 to 2.12), respectiely.

开始治疗5年后，有79％病人继续使用肾素血管紧张素抑制剂，65％用阻滞剂，56％用安体舒通，83％使用他汀类，值得注意的是，联合用药和心衰的加重同坚持治疗相关，无法坚持使用肾素血管紧张素抑制剂，阻滞剂，安体舒通，他汀类药物的病人同增加的死亡率相关，其死亡危险比分别为1.37 (95%可信区间， 1.31 － 1.42)， 1.25 (95%可信区间， 1.19 － 1.32)， 1.88 (95%可信区间， 1.67 － 2.12)，。

Cardiac hypertrophy and extracellular matrix remodeling happened as a result of chronic overrange of pressure in heart and hypervolaemia which lead to damage of relaxation and compliance of heart.Drugs including renin-angiotensin converting enzyme inhibitor,angiotensin receptor blocker,aderergic receptor blocker,aldrosteron antagonism,tatins endothelin receptor blocker pancreatic kiniogenase and calcalium channel blocker,can delay or reverse the remodeling by several mechanisms.

主要表现为心脏在慢性超负荷的压力、容量作用下发生的病理改变致使左室肥厚组织胶原结构发生改变，导致心肌顺应性降低，舒张功能受到损害；作用于肾素-血管紧张素系统的药物及肾上腺素受体阻滞剂、醛固酮拮抗剂、他汀类药物、内皮素受体拮抗剂、胰激肽原酶、钙通道阻滞剂等药物通过不同途径和机制延缓和逆转左心室重构。

Diuretics, beta blockers, and calcium channel blockers are the most commonly used drugs for high blood pressure and although in most cases these dugs bring success, if they fail to bring a person's blood pressure under control then other classes of drugs may be introduced.

利尿剂，β阻滞剂，钙通道阻滞剂是最常用的药物，血压高的压力，虽然在大多数情况下，这些dugs带来成功，如果他们失败，使一个人的血压已受到控制，然后其他类别的药物可能会介绍。

Per the average price of drugs from low to high as follows: Thiazide diuretics,β-receptor blockers, angiotensin-converting enzyme inhibitor, calcium channel blocker, angiotensin II receptor blocker.

按每类药物的平均价格由低到高依次为：噻嗪类利尿剂、β—受体阻滞剂、血管紧张素转换酶抑制剂、钙通道阻滞剂、血管紧张素II受体拮抗剂。

Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) recommends treating most patients with stage 2 hypertension (160/100 mm Hg or higher) with a two-drug combination of a thiazide diuretic plus an ACE inhibitor, angiotensin receptor blocker, beta blocker, or calcium channel blocker.

美国国家联合委员会关于高血压预防、诊断、评估与治疗第七次报告（JNC 7）建议，大多数2期高血压（≥160/100 mm Hg）患者应接受一种噻嗪类利尿剂加一种血管紧张素转换酶抑制剂、血管紧张素受体阻滞剂、β受体阻滞剂或钙通道阻滞剂的两药联合方案治疗。

与阻滞剂相关的网络解释 [注：此内容来源于网络，仅供参考]

blocker：阻滞剂

化学物质225H发现于两栖动物体内.一种在两栖动物身上发现的化学物质225H是离子通道阻滞剂(blocker). 这意味着它可以改变神经系统的"总开关",这一发现对神经系统科学研究人员来说具有重大意义. 225H还被用作止痛药,或是用以帮助吸烟者戒烟.

Nitrosamine blockers：亚硝铵阻滞剂

63. 益母草Motherwort | 65. 亚硝铵阻滞剂Nitrosamine blockers | 67. 燕麦麸Oat bran

retarder：阻滞剂

retarded ignition 延迟点火 | retarder 阻滞剂 | retarding agent 阻滞剂

retarding agent：阻滞剂

retarder 阻滞剂 | retarding agent 阻滞剂 | retention time 保留时间

retarding agent：缓聚剂,阻滞剂

缓聚剂 retarder | 缓聚剂,阻滞剂 retarding agent | 阻聚剂 inhibitor

ARB：血管紧张素受体阻滞剂

而检查结果为阴性的患者新华社信息北京12月15日电 美国阿拉巴马大学的研究人员认为,在已 经应用包括一种利尿剂和一种血管紧张素转换酶(ACE)抑制剂或血管紧张素受 体阻滞剂(ARB)在内的多药物方案的伴或不伴原发性醛固酮增多症患者中,

AII receptor blockers：血管紧张素II受体阻滞剂

A-H interval A-H 间期 | AII receptor blockers 血管紧张素II受体阻滞剂 | air embolism in heart 心脏空气栓塞

calcium channel blockers：钙通道阻滞剂引起的有害效应

粘液囊钙沉着 Calcium deposit in bursa | 钙通道阻滞剂引起的有害效应 Calcium-channel blockers | 膀胱结石 Calculus in bladder

muscarinic blocker：毒蕈碱受体阻滞剂

mural thrombus 心内附壁血栓 | muscarinic blocker 毒蕈碱受体阻滞剂 | muscular dystrophy 肌营养不良

Retardants：阻滞剂

RESS超临界溶液快速膨胀技术 | Retardants阻滞剂 | Reverseosmosis反渗透